BG Medicine reports data for CardioScore

BG Medicine Inc. (NASDAQ:BGMD) said that testing with its CardioScore diagnostic at baseline significantly improved the identification of subjects at high risk for near-term major cardiovascular events over conventional risk scoring throughout a median follow-up of 2.5 years in the pivotal BioImage Study. The U.S. trial enrolled 6,600 subjects with no prior history of cardiovascular disease. Last December, BG Medicine submitted a 510(k) application to FDA for the CardioScore test to identify patients at high risk for near-term major cardiovascular events, including myocardial infarction (MI) and stroke. CardioScore is an in vitro diagnostic multivariate index (IVDMIA) assay that measures seven protein biomarkers in blood. ...